Quick Overview.
Humanin (HN) is a groundbreaking micropeptide that is entirely unique in the world of biology: it is encoded not by the DNA in the cell nucleus, but by the DNA inside the mitochondria (the energy-producing powerhouses of the cell). Discovered in 2001 by Japanese researchers studying the brains of Alzheimer's patients, Humanin was found in the surviving, healthy neurons of the brain, suggesting it was actively protecting them from death.[1]
In the longevity and biohacking communities, Humanin is considered a master cytoprotective (cell-protecting) peptide. It is one of the first known Mitochondrial-Derived Peptides (MDPs). Its primary function is to protect cells from oxidative stress, apoptosis (programmed cell death), and the accumulation of toxic amyloid plaques. Research has shown that natural Humanin levels decline steadily with age, and supplementing it or its more potent analogs (like HNG) is linked to improved healthspan and increased lifespan in animal models.[2]
- Primary Use Case: Neuroprotection, Alzheimer's disease prevention, cardiovascular health, and systemic anti-aging.
- Mechanism: Binds to specific receptors (like the CNTFR/WSX-1/gp130 complex) and interacts directly with Bax (a pro-apoptotic protein) to prevent mitochondrial dysfunction and cell death.[3]
- Who it is for: Advanced biohackers focused on extreme longevity, individuals with a family history of neurodegenerative diseases, or those recovering from ischemic events (like heart attacks or strokes).
- Who it is NOT for: Individuals with active, aggressive cancers. Because Humanin prevents cell death (apoptosis), it could theoretically protect cancer cells from dying during chemotherapy.
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
confidence_tier: experimental
Humanin is still largely in the research phase, and human clinical protocols are not as standardized as older peptides like BPC-157. The most commonly used version in research is HNG (Humanin G), a synthetic analog where the 14th amino acid (Serine) is replaced by Glycine, making it up to 1000 times more potent than naturally occurring Humanin.
Standard Dosing Schedule
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Standard Longevity (HNG) | 1 mg to 2 mg | 2-3x per week | SubQ Injection |
| Neuroprotection / Recovery | 2 mg to 5 mg | 1x daily | SubQ Injection |
Cycle Length & Discontinuation Protocol
- Cycle Length: Due to its potent anti-apoptotic effects, it is generally recommended to cycle Humanin rather than use it continuously year-round. A common protocol is 4 to 6 weeks on, followed by 4 to 6 weeks off.
- Timing: Can be injected at any time of day, though morning is preferred to align with natural metabolic rhythms.
- Discontinuation: Can be stopped abruptly.
Nutritional Support & Recommended Supplements.
confidence_tier: community
| Supplement | Rationale | Recommended Dose |
|---|---|---|
| NMN or NR | Humanin protects the mitochondria, while NAD+ boosters (NMN/NR) fuel them. This is a highly synergistic mitochondrial anti-aging stack. | 500-1000mg daily. |
| Coenzyme Q10 (Ubiquinol) | Supports the mitochondrial electron transport chain, enhancing the overall metabolic efficiency that Humanin protects. | 100-200mg daily. |
| PQQ (Pyrroloquinoline Quinone) | Stimulates mitochondrial biogenesis (the creation of new mitochondria), complementing Humanin's protection of existing mitochondria. | 20mg daily. |
Safety, Interactions & Side Effect Management.
confidence_tier: experimental
Side Effect Profile
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Injection Site Reaction | Mild | Occasional | Rotate injection sites and ensure proper reconstitution with bacteriostatic water. |
| Hypoglycemia (Mild) | Mild | Rare | Humanin improves insulin sensitivity. Monitor blood sugar if taking alongside Metformin or insulin. |
Contraindications
- Absolute: Active cancer diagnosis. The primary mechanism of Humanin is to stop apoptosis (cell death). In cancer, apoptosis is exactly what you want to happen to the tumor cells. Taking a potent anti-apoptotic peptide like Humanin could theoretically accelerate tumor progression or cause chemo-resistance.[4]
- Relative: Pregnancy and breastfeeding, due to a lack of safety data.
Common Stacks & Combinations.
confidence_tier: community
| Stack | Goal | Rationale |
|---|---|---|
| The Mitochondrial Stack | Maximum Healthspan | Humanin (HNG) + MOTS-c + SS-31. This combines the three most powerful mitochondrial peptides. Humanin protects against cell death, MOTS-c improves metabolic efficiency, and SS-31 repairs the inner mitochondrial membrane. |
| Humanin + Cerebrolysin | Neuro-Regeneration | Humanin protects neurons from amyloid toxicity, while Cerebrolysin (BDNF) stimulates the growth of new neural pathways. |
Body Composition & Training Guide.
confidence_tier: experimental
- Insulin Sensitivity: Humanin has been shown to act centrally (in the hypothalamus) to improve peripheral insulin sensitivity. This can indirectly aid in nutrient partitioning and fat loss.
- Endurance: By protecting mitochondrial function under stress, Humanin may delay the onset of muscular fatigue during intense aerobic exercise, though it is not primarily used as a performance-enhancing drug.
Storage, Handling & Accessibility.
confidence_tier: well-established
- Storage: Lyophilized powder must be stored in the freezer. Once reconstituted with bacteriostatic water, it must be kept in the refrigerator and used within 30 days.
- WADA Status: Unclear. Falls under the blanket ban of unapproved peptide hormones.
- Accessibility: Available strictly as a research chemical. It is relatively rare and expensive compared to standard peptides.
Bloodwork Monitoring Guide.
confidence_tier: community
| Biomarker | When to Test | Why it Matters |
|---|---|---|
| Fasting Insulin & HbA1c | Baseline, Week 6 | To monitor the peptide's positive effects on systemic insulin sensitivity. |
| hs-CRP | Baseline, Week 6 | High-sensitivity C-Reactive Protein. Humanin should lower systemic inflammation. |
Comparison to Similar Compounds.
confidence_tier: well-established
| Feature | Humanin (HNG) | MOTS-c | SS-31 (Elamipretide) |
|---|---|---|---|
| Origin | Mitochondrial DNA | Mitochondrial DNA | Synthetic |
| Primary Mechanism | Anti-Apoptotic (Prevents cell death) | AMPK Activator (Metabolic) | Cardiolipin Binder (Membrane repair) |
| Best For | Neuroprotection / Alzheimer's | Weight Loss / Insulin Resistance | Heart Failure / Severe Fatigue |
| Cancer Risk | Theoretical Risk (Anti-apoptotic) | Low | Low |
Deep Dive (For Advanced Researchers).
confidence_tier: well-established
The Discovery of Mitochondrial-Derived Peptides (MDPs)
For decades, biologists believed that the small, circular DNA inside mitochondria only coded for 13 proteins, all of which were structural components of the electron transport chain. The discovery of Humanin shattered this dogma.
- Humanin is encoded by a short open reading frame (sORF) within the 16S ribosomal RNA gene of the mitochondrial genome.
- It proved that mitochondria actively secrete signaling peptides into the cytoplasm and the bloodstream to communicate with the rest of the body, a process known as retrograde signaling.[5]
Neuroprotection and Alzheimer's Disease
Humanin was discovered by screening for survival factors in the brains of Alzheimer's patients.
- Amyloid Beta Toxicity: In Alzheimer's disease, the accumulation of Amyloid Beta (Aβ) plaques causes massive oxidative stress and triggers apoptosis in neurons. Humanin binds directly to Aβ peptides, preventing them from forming toxic oligomers and protecting the neurons from death.[6]
- APOE4 Carriers: A fascinating 2024 study found that a specific genetic variant of Humanin (P3S) is associated with extreme longevity in humans who carry the APOE4 gene (the highest genetic risk factor for Alzheimer's). The Humanin variant actively resisted the brain pathology normally induced by APOE4.[7]
Cardiovascular Protection
Beyond the brain, Humanin is highly protective of the cardiovascular system.
- During a heart attack (myocardial infarction), the sudden loss of oxygen (ischemia) followed by the sudden rush of oxygen (reperfusion) causes massive mitochondrial damage and cell death in the heart muscle.
- Administration of Humanin prior to or during ischemia-reperfusion injury significantly reduces the size of the cardiac infarct (dead tissue) by preserving mitochondrial function and blocking the Bax apoptotic pathway.[8]
Frequently Asked Questions (FAQ).
confidence_tier: community
Q: What is the difference between Humanin and HNG? A: Natural Humanin is 24 amino acids long. HNG (Humanin G) is a synthetic analog where the 14th amino acid (Serine) is replaced by Glycine. This single amino acid swap makes HNG up to 1,000 times more potent at protecting cells from death. Almost all research chemicals sold are the HNG version.
Q: Can I take this if I have a family history of cancer? A: It is highly advised to consult an oncologist. While Humanin does not cause cancer, its primary job is to keep cells alive. If a cell turns cancerous, you want it to undergo apoptosis (die). Humanin could theoretically prevent that natural defense mechanism.
Q: Does it cross the blood-brain barrier? A: Yes. Despite being a peptide, Humanin has been shown to cross the blood-brain barrier, which is why systemic subcutaneous injections can exert profound neuroprotective effects in the brain.
International Regulatory Status.
confidence_tier: well-established
| Agency | Status | Notes |
|---|---|---|
| US FDA | Not Approved | Strictly a research chemical. No approved clinical applications yet. |
| WADA | Unclear | Falls under general peptide restrictions. |
| Global | Investigational | Currently the subject of intense academic research for age-related diseases. |
Decision Tree.
confidence_tier: community
[Goal: Extreme Neuroprotection or Mitochondrial Anti-Aging?]
|
+-- Do you have an active cancer diagnosis or high risk of cancer?
|
+-- (Yes) -> DO NOT USE. Humanin prevents cell death and could protect tumor cells.
|
+-- (No) -> Inject 1-2mg of HNG (Humanin G) SubQ, 2-3 times per week.
|
+-- Cycle for 4-6 weeks.
|
+-- Take 4-6 weeks off to allow natural apoptotic clearing of senescent cells.Schema.org Data.
{
"@context": "https://schema.org",
"@type": "MedicalEntity",
"name": "Humanin",
"alternateName": ["HN", "HNG", "Humanin G"],
"description": "A mitochondrial-derived micropeptide that acts as a potent cytoprotective agent. It prevents apoptosis, protects against oxidative stress, and is heavily researched for its ability to protect neurons from Alzheimer's disease pathology.",
"legalStatus": {
"@type": "DrugLegalStatus",
"description": "Not approved by the FDA. Sold strictly as a research chemical."
}
}What we cited.
- Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001;98(11):6336-6341. doi:10.1073/pnas.101133498
- Yen K, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(11):103534. doi:10.18632/aging.103534
- Lee C, et al. Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. 2013;24(4):222-228. doi:10.1016/j.tem.2012.11.001
- Moreno Ayala MA, et al. Humanin Promotes Tumor Progression in Experimental Breast Cancer. Sci Rep. 2020;10(1):8286. doi:10.1038/s41598-020-65381-7
- Coradduzza D, et al. Humanin and Its Pathophysiological Roles in Aging: A Systematic Review. Biology (Basel). 2023;12(4):558. doi:10.3390/biology12040558
- Levine ZA, et al. The Mitochondrial Peptide Humanin Targets but Does Not Disrupt the Amyloid-β Fibril Architecture. Biochemistry. 2019;58(40):4089-4095. doi:10.1021/acs.biochem.9b00624
- Yen K, et al. Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology. Aging Cell. 2024;23(7):e14101. doi:10.1111/acel.14101
- Rochette L, et al. Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders. Arch Cardiovasc Dis. 2020;113(10):655-664. doi:10.1016/j.acvd.2020.05.004